The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.

Systems and methods for classifying T cells by activation state are disclosed. The system includes a cell analysis pathway, a time-resolved autofluorescence decay spectrometer, a processor, and a non-transitory computer-readable memory. The memory is accessible to the processor and has stored thereon instructions. The instructions, when executed by the processor, cause the processor to: a) receive the time-resolved autofluorescence decay signal; b) compute at least a first phasor coordinate at a first frequency and a second phasor coordinate at a second frequency from the time-resolved autofluorescence decay signal, wherein the first and second frequency are different; and c) compute an activation prediction for the T cell using at least the first phasor coordinate and the second phasor coordinate.

Disclosed is a method for the dissociation of cells. Cells are processed under varying conditions of pH, temperature, and shear to thereby produce different cell products. In one form, the cells are jet cooked at a lower temperature and/or pressure to provide products that are relatively delicate. The remaining cell components may then be subsequently jet cooked under higher temperature and/or shear conditions to provide products that are relatively more robust. Generally, the cells become dissociated, whereby at least one separate cell wall component is substantially separate from the dissociated cell walls.

The present invention relates to a method for in vitro production of red blood cells. The method for in vitro production of red blood cells, according to the present invention, specifies, by cell size, the maturation step of cells exhibiting optimal effects in an agitation-type culture, so that even if an expert does not always identify cell shape, automated processes of culturing are possible, and thus automation in bioreactors is possible in the mass-production of uniform quality and red blood cells.

The disclosure is directed to technologies for restoring proper regulation of the immune response and novel methods and systems for exogenously controlling immune cells in order to dynamically and predictively drive the immune response through pro-inflammatory activity to anti-inflammatory activity, mimicking the immune system's natural progression through these states. Embodiments of the present disclosure relate generally to methods and systems for dynamic predictive modeling and control of inflammation and the immune response, and more specifically to methods and systems for predictive modeling and control of the inflammatory state of immune cells via temporally regulated immune-modulating stimuli.

Embodiments described herein generally provide for expanding cells in a cell expansion system. The cells may be grown in a bioreactor, and the cells may be activated by an activator (e.g., a soluble activator complex). Nutrient and gas exchange capabilities of a closed, automated cell expansion system may allow cells to be seeded at reduced cell seeding densities, for example. Parameters of the cell growth environment may be manipulated to load the cells into a particular position in the bioreactor for the efficient exchange of nutrients and gases. System parameters may be adjusted to shear any cell colonies that may form during the expansion phase. Metabolic concentrations may be controlled to improve cell growth and viability. Cell residence in the bioreactor may be controlled. In embodiments, the cells may include T cells. In further embodiments, the cells may include T cell subpopulations, including regulatory T cells (Tregs), for example.

A method of purifying adipose-derived mesenchymal stem cells from a sample of adipose tissue, including: flowing the sample onto a polymer surface having at least one vertical helical-shaped portion, vertical threaded shaped portion, or vertical grooved shaped portion at a first flow rate of 10 to 150 ml/min allowing separation into a first remaining sample including mesenchymal stem cells on the polymer surface and into a second resulting solution being evacuated from the polymer surface; flowing a saline solution onto the polymer surface at a second flow rate of 100 to 500 ml/min, the first flow rate being slower than the second flow rate; and collecting the saline solution including purified mesenchymal stem cells in a collector. Also, an apparatus and a system for purifying adipose-derived mesenchymal stem cells, the use of the apparatus, and a method of isolating and purifying adipose-derived mesenchymal stem cells from an adipose tissue sample.

This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.

This disclosure pertains to a non-living biological product. Particularly, exosomes derived from stem cells can help restore heart function. According to certain embodiments, a fluid-induced shear stress mechanical stimulation process of stem cells is used to augmented quantity and quality of exosomes produced from stem cells. These exosomes serve as a therapeutic agent for the regenerative repair of diseases, such as diseased heart tissues. Therefore, compositions comprising the exosomes derived from stem cells and methods of treating a degenerative disease by administering the exosomes isolated from stem cells are also provided.

The present disclosure provides methods and systems for the large-scale generation of differentiated stem cells. The present disclosure is also directed to systems and methods for expanding and differentiating stem cells in large-scale culture using a bioreactor chamber.